<DOC>
	<DOCNO>NCT00632242</DOCNO>
	<brief_summary>To evaluate overall safety tolerability ARC1779 , therapeutic oligonucleotide ( `` aptamer '' ) patient three type von Willebrand Factor relate platelet disorder .</brief_summary>
	<brief_title>ARC1779 Injection Patients With Von Willebrand Factor-Related Platelet Function Disorders</brief_title>
	<detailed_description>ARC1779 Injection investigate 4 cohort TTP patient uncontrolled , open-label study . Patients vWD-2b enrol additional cohort randomize , blind , double-dummy , placebo-controlled study . Collectively , patient represent 3 different vWF-related platelet function disorder : TTP remission , acute TTP , vWD-2b treat total 5 cohort . Three cohort consist patient status post episode TTP ( `` TTP Remission Cohorts '' ) treat ARC1779 Injection dose- duration-escalation design . In parallel , single cohort patient acute TTP ( `` Acute TTP Cohort '' ) treat accord individual patient titration-to-response paradigm . This cohort open enrollment beginning study close cohort complete . Also parallel , single cohort patient vWD-2b ( `` vWD-2b Cohort '' ) begin enrollment commencement study continue independently course TTP Remission Cohorts . Up 4 patient include TTP cohort . The vWD-2b Cohort expect consist 12 vWD-2b patient .</detailed_description>
	<mesh_term>Purpura</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Purpura , Thrombotic Thrombocytopenic</mesh_term>
	<mesh_term>Von Willebrand Disease , Type 2</mesh_term>
	<mesh_term>Deamino Arginine Vasopressin</mesh_term>
	<criteria>Male female ; Age 1875 year ; vWD2b confirm diagnosis , ; TTP Remission prior episode ( ) primary acute TTP , ; Acute TTP episode , first relapse , presence following : 1 . Microangiopathic hemolytic anemia ( schistocytosis present , Coombs test negative ) ; 2 . Severe thrombocytopenia ; 3 . Clinical diagnosis either primary secondary form TTP : ( 1 ) Primary TTP : e.g. , familial TTP ( UpshawSchulman syndrome ) , acquire idiopathic TTP , `` atypical HUS '' ; ( 2 ) Secondary TTP : e.g. , TTP occur postbone marrow transplant , druginduced TTP , lupusrelated TTP , etc . ; Negative qualitative urine drug test screening , history alcohol drug abuse ; Not consider schedule undergo surgical procedure duration study ; Has donate lose unit blood within 30 day prior screen visit ; Has receive experimental drug within 30 day prior screen ; Female patient must nonpregnant [ TTP Remission vWD2b Cohorts , serum pregnancy test screen urine pregnancy test Day 1 predose must negative ; Acute TTP Cohort , serum pregnancy test Day 1 predose must negative ] , willing use effective , redundant method contraception ( i.e. , self male partner ) throughout study least 30 day participation . If possible , treatment initiate within 5 day cessation precede menstrual period ; Male patient must agree use medically acceptable contraceptive ( abstinence use condom spermicide ) throughout study least 30 day participation ; Patients must capable understand comply protocol must sign informed consent document prior performance studyrelated procedure . History recent surgery trauma ; Any major , active health problem , e.g. , cancer heart disease , could render patient medically unstable period participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>